Trial Profile
A Randomized, Double-blind, Placebo-controlled Multicenter Dose Ranging Study to Assess the Safety and Efficacy of Multiple Oral ZPL389 Doses in Patients With Moderate to Severe Atopic Dermatitis (ZEST Trial)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2022
Price :
$35
*
At a glance
- Drugs Adriforant (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms ZEST Trial
- Sponsors Novartis; Novartis Pharma KK; Novartis Pharmaceuticals
- 21 Jan 2022 This trial has been completed in Iceland (Date of the global end of the trial : 07-Jun-2018), according to European Clinical Trials Database record.
- 18 Aug 2020 Status changed from recruiting to discontinued.
- 15 Aug 2020 This trial has restarted recruitment in Germany.